Jared Whitlock

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began looking outside the US for a place to ...

China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains in a rut. Buoyed by licensing deals, improving company fundamentals and regional ...

A congressional commission is advocating for a $15 billion federal investment in America’s biotechnology sector, warning that the US could soon be eclipsed by China in a key frontier of ...

CEO Jacob Thaysen leads Illumina's expansion into multiomics beyond DNA sequencing, facing competition from Roche and Chinese restrictions while making strategic acquisitions.

Jill Wood had pinned her hopes on a little-known federal program to fund her son’s gene therapy. The initiative, which awards vouchers to companies targeting rare pediatric diseases, offered her ...

Renee Wegrzyn has been let go as the head of a federal agency that pursues ambitious ideas to accelerate biomedical innovation, part of a broad series of ongoing changes being made by the new Trump administration.

A series of actions by President Donald Trump's administration have provoked profound anxiety among academic labs that undergird biomedical research.

China blacklists Illumina amid tensions with the US, threatening its market access, while US actions limit Chinese rival MGI; CEO Jacob Thaysen seeks resolution as stock falls.

In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers. Shortly after, they did what many researchers ...

President-elect Donald Trump’s two picks for the Federal Trade Commission are likely to usher in more life sciences deals while maintaining the agency’s pressure on pharmaceutical intermediaries.

Two years ago, GeneDx was teetering. The genetic testing company had laid off 33% of its staff, shares were down 90% from a year prior, and some investors were skeptical of a turnaround plan. Since then, GeneDx has quietly managed a comeback.

Neurogene's stock {$NGNE} fell 35% in post-market trading on Monday after a Rett syndrome patient who received a high dose of the company's gene therapy experienced a serious adverse event ...

Scientists have unveiled a strategy for targeting a vulnerability in tiny circles of floating DNA that can drive aggressive cancers. These circles — known as extrachromosomal DNA, or ecDNA, because they ...

As the head of the trade group BIO and a parent to children with a rare disease, John Crowley is personally and professionally at the center of a bill targeting ...

In March, Paul Schneider was diagnosed with pancreatic cancer. The 77-year-old retired firefighter was grateful to receive the news. He was symptom-free, and a blood test from the company Grail ...

Ravinder Dhallan’s name is on key patents in noninvasive prenatal testing, a field that has reshaped screening for expectant mothers. But he was a minor figure in the $3.8 billion ...

When Julia Taravella’s two sons were diagnosed with an ultra-rare disease, she did something extraordinary but not uncommon among parents like her: She formed a group that raised $1.2 million ...

Taysha Gene Therapies CEO RA Session II has resigned following a turbulent year in which the company shelved most of its rare disease pipeline and faced criticism from families for ...